Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease incidence in metabolically healthy and unhealthy normal weight obesity
Authors' conclusion
MRFs may modulate CVD and MASLD risk in NWO.
Study context
- Population
- Subjects with normal weight obesity (NWO) (normal body mass index (BMI), elevated body fat), overweight/obesity or normal weight lean
- Participants
- 121,586 subjects
- Exposure
- Metabolically healthy and unhealthy NWO and OW/O vs healthy normal weight lean
- Outcome
- Incident CVD and MASLD
Methodological detailsFirth logistic regression, quantile regression, false discovery rate <0.05
- Firth logistic regression
- Quantile regression
- False discovery rate <0.05
Main finding
As reported in the abstract
Each group vs normal weight leanEstimate (95% CI)P value
MU-NWO
OR (ischemic heart disease) 1.68(1.36–2.05)
FDR = 0.000007MU-NWO
OR (MI) 1.72(1.38–2.11)
FDR = 0.000007MU-NWO
OR (all-cause mortality) 1.29(1.05–1.56)
FDR = 0.02MU-NWO
OR (CVD death, I0-I99) 1.86(1.27–2.64)
FDR = 0.0036MH-NWO
OR (MASLD, females) 1.37(1.04–1.78)
FDR = 0.03MU-NWO
OR (MASLD, females) 1.78(1.05–2.83)
FDR = 0.03Observational data: associations, not effects.
Secondary outcomes
Cardiac/liver imaging, serum liver enzymes and lipid biomarkers · cross-sectional
- Biochemical and imaging data were consistent with enhanced cardiovascular disease (CVD) and MASLD risk
Original publication
Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease incidence in metabolically healthy and unhealthy normal weight obesity. Int J Obes (Lond). Published 17 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →